Alnylam launches digital tool for AATR amyloidosis patients

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track their symptoms. The new app – called STAR – allows patients to record their symptoms and share them with healthcare professionals to …

Alnylam launches digital tool for AATR amyloidosis patients Read More »